arrow
Y

Yingying Su

xia men university
H指数:29
被引数:6,255

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China

健康女性中高危型人乳头瘤病毒感染的类型和年龄特异性自然史:一项中国前瞻性队列研究

2026-01-160
OA
Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18–26 years: three-year follow-up data from a randomised clinical trial

中国18~26岁女性中由大肠杆菌生产的九价人乳头瘤病毒疫苗与Gardasil9的免疫原性比较:一项随机临床试验的三年随访数据

2025-08-270
PREAI
Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort

大肠杆菌生产的HPV-16/18双价疫苗的长期疗效和免疫持久性:一项针对随机、双盲III期临床试验队列的观察性扩展研究

2025-08-210
OAAI
Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study

乙型肝炎表面抗原阳性成人中,针对医疗就诊症状性感染的戊型肝炎疫苗的有效性:一项以非确诊病例为对照的研究

2025-02-172
OA
The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort study
2024-12-130
PRE
Immunogenicity and safety of an ORF7-deficient skin- attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2atrial

水痘ORF7-deficient皮肤减毒和神经减毒活疫苗的免疫原性和安全性: 随机,双盲,对照,2期心房

2024-08-011
PRE
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

重组戊型肝炎疫苗在成人中的长期疗效: 一项随机,双盲,安慰剂对照,3期试验的10年结果

LANCET
IF88.5
2024-03-0113
PRE
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2023-12-0122
OAAI
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
2023-11-0111
PRE
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
2023-10-016
OAAI